Neonates exposed to excipients: concern about safety by Cuzzolin, Laura
1/10
www.jpnim.com Open Access eISSN: 2281-0692
Journal of Pediatric and Neonatal Individualized Medicine 2018;7(1):e070112
doi: 10.7363/070112 
Received: 2017 May 10; accepted: 2017 Jul 28; published online: 2017 Dec 24
Neonates exposed to excipients: 
concern about safety
Laura Cuzzolin
Department of Diagnostics & Public Health – Section of Pharmacology, University of Verona, Verona, 
Italy
Abstract
Excipients are generally perceived as inert and pharmacologically inactive. 
Instead, serious adverse reactions have been reported in vulnerable patient 
populations and little is known about exposure of newborns to excipients. 
The aim of this review is to deepen the presence of potentially harmful 
excipients in drugs commonly used in neonates. From an analysis of articles 
and case reports present in the international literature emerges that several 
medicines administered to newborns contain potentially harmful excipients 
such as ethanol, propylene glycol and benzyl alcohol. Neonatologists should 
be aware of this problem and possibly prescribe substitutive treatments.
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Introduction
Due to their unique physiology, neonates are particularly vulnerable to 
drug treatments and the effects of active compounds and excipients present 
in pharmaceutical preparations can be different compared to children and 
adults [1]. 
Usually, the interest about safety is focused on active compounds and 
excipients are supposed to be pharmacologically inactive [2]. Instead, certain 
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excipients present in medicines commonly used in 
the neonatal population are currently recognised as 
toxic to newborns if they are given at high doses [3-
6] and occasional reports referred serious adverse 
events in neonates [7-10]. Taking into account 
that critically ill newborns admitted to NICUs 
receive many medicines and then may be exposed 
to different excipients per day, this merits great 
concern suggesting that also excipients should be 
labelled with sufficient composition information and 
excipient-free formulations should be considered 
whenever possible [3, 4].
In this article we will give an updated overview 
of the worldwide situation in the neonatal population 
as regards the exposure to excipients potentially 
harmful. For this reason, some considerations about 
availability of formulations for neonates will be 
discussed and an analysis of the literature will be 
made.
Excipients and age-appriopriateness of for-
mulations for neonates
With the term excipient we refer to every 
inert agent present in a formulation (solvents, 
diluents, emulsifiers, preservatives, sweeteners...) 
added with the scope to confer shape, volume and 
consistency to the pharmaceutical preparation, to 
stabilize the active drug, to enable its bioavailability 
and deliver the active principle to its site of action, 
to ensure an easy administration and favouring the 
compliance [2]. 
Usually, safety data available for excipients 
derive from adults, while information in neonates 
and children is often missing [11]. Excipients that 
have not caused problems in adults are assumed to 
be safe in neonates, despite significant differences 
in pharmacokinetics and pharmacodynamics [6].
The Committee for Medicinal Products for 
Human Use guideline about excipients states that 
“excipients to be used in formulations for the 
paediatric population should be selected with special 
care and possible sensitivities of the different age 
groups should be taken into consideration” [12]. 
Despite this, while since 2010 new medications 
authorized in Europe have to specify quantitative 
details of excipients in the Summary of Product 
Characteristics (SPCs) [13], many paediatric 
formulations licensed before the European Pediatric 
Regulation contain excipients not recommended 
for use in neonates [14]. In addition, many drugs 
administered to neonates are still not licensed for 
this paediatric subpopulation leading to a common 
use of extemporaneous or magistral preparations 
and off-label medications in absence of suitable 
commercial formulations [15]. 
The development of feasible formulations 
represents a challenge for the neonatal population, 
characterized by unique needs. Many drugs used in 
newborns do not exist in a suitable dosage form to 
allow administration to a neonate. Therefore, adult 
formulations need to be manipulated to obtain an 
age-appropriate product. This implies that some 
excipients should be added to the original product 
for many reasons, for example to stabilise the new 
formulation or to make it palatable [6]. A drug 
should have a good taste to ameliorate palatability of 
oral liquid formulations and parenteral preparations 
should contain small dose volumes and should be 
administered using small needles [2]. To achieve 
this, a lot of excipients are commonly used in 
paediatric formulations, exposing particularly 
neonates and infants, characterized by a different 
pharmacokinetic behaviour, to potentially serious 
adverse events. The European Medicines Agency 
(EMA) reflection paper states that “manipulation of 
adult medicinal products for paediatric use should 
be the last resort”, but at the same time underlines 
that “this is recognized as an unavoidable and 
necessary operation in many cases” [16].
In the Netherlands, about half of the oral liquid 
preparations and 7% of the parenteral formula-
tions contain potentially harmful excipients [17], 
favouring the use of unlicensed preparations. 
Therefore, the choice of excipients and of their 
dosage is a major challenge that should be justified 
through a risk-based assessment, taking into 
account different factors including the convenience 
of administration and the flexibility of the dosage 
form: in a paediatric formulation, the number of 
excipients and their level should be the minimum 
required to ensure an appropriate product with 
respect to performance, stability, palatability, dose 
uniformity [18]. The European Study of Neonatal 
Exposure to Excipients (ENSEE) aims to provide 
an evidence base for discussion about the safety 
of medicines given to newborns by determining 
the exposure of neonates to excipients, comparing 
variations within and between regions, and 
measuring concentrations of excipients in the 
blood of babies routinely treated [19]. 
Surely, medicines containing excipients have 
benefits and these benefits in many cases will not 
be possible in absence of excipients. However, 
any excipient present in a formulation should not 
pose unacceptable risks for the neonate [4]. For 
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identification of excipients in each medication, the 
SPCs is the best available source.
Excipients potentially harmful for neonates 
A wide range of excipients has been related to 
potential harm in neonates, even if a limited number 
of these harms resulted fatal or disabling.
Solvents such as ethanol and propylene glycol 
are often present in formulations for newborns and 
infants to improve drug solubility. 
Ethanol is found in many oral liquid 
preparations (for example furosemide and 
ranitidine preparations, iron supplementations) 
and together with its metabolite acetaldehyde 
could have synergic negative effects on central 
nervous system, as observed when in association 
with dextromethorfan, present in an over-the-
counter (OTC) cough syrup [20]. In Italy [21] and 
in the UK [14, 22], many commercially available 
preparations for neonates have the potential to 
deliver significant amounts of ethanol and other 
authors found that 14 formulations routinely used 
in NICUs contain ethanol [23]. The U.S. Food and 
Drug Administration (FDA) issued a guidance on 
the ethanol content of OTC medications indicating 
in 0.5% the maximum concentration for subjects 
under 6 years [24], while the EMA published a 
draft for the guideline on “Excipients in the label 
and package leaflet of medicinal products for 
human use” containing detailed information on 
ethanol content, comprised thresholds for different 
age groups [25].
Propylene glycol, a solvent with antimicrobial 
properties, is one of predominant excipients present 
in medications routinely administered to critically ill 
neonates. High doses of propylene glycol have been 
associated with respiratory, cardiovascular, central 
and hepatic adverse effects in newborns [26, 27] 
probably due to accumulation of propylene glycol 
and its metabolites in presence of limited hepatic and 
renal elimination capacity [28]. A FDA drug safety 
communication underlined serious health problems 
in preterm neonates exposed to an oral solution 
of lopinavir/ritonavir containing propylene glycol 
[29]. This solvent is present in dexamethasone 
preparations, commonly used in NICUs to treat 
chronic pulmonary disease, in concentrations that 
largely exceed the acceptable intake limit for adults 
[14, 30]. Sources of intravenous propylene glycol 
exposure in neonates regard also other drugs such 
as diazepam, digoxin, lorazepam, nitroglycerin and 
phenobarbital [31].
Neonates exposed to excipients: concern about safety
Exposure to peanut oil, present as solvent 
in intramuscular injections and in topical 
formulations for the prevention and treatment of 
the genital dermatitis, could lead to episodes of 
hypersensitivity [2]. 
The use of preservatives in medicines intended 
for newborns requires special consideration 
and preservative-free formulations should be 
considered whenever possible. 
Among preservatives, benzalkonium 
chloride, frequently present in beclometasone 
and ipratropium bromide nebulizer solutions 
and in topical medications such as nasal saline 
and decongestants, has been associated with 
bronchospasm in paediatric patients [32].
Another commonly used preservative is 
benzyl alcohol, known to determine metabolic 
acidosis, seizures and gasping. Benzyl alcohol 
partially undergoes hepatic oxidative metabolism 
to benzoic acid: a reduced metabolic capacity 
to inactivate benzoic acid to hippuric acid has 
been suggested as the underlying mechanism 
of benzyl alcohol toxicity in newborns [33]. 
Intravenous formulations of some corticosteroids 
(betamethasone and triamcinolone) contain benzyl 
alcohol, contraindicated in newborns as it can 
induce anaphylactic reactions under 3 years of life 
[34] and the routine use of continuous infusions 
of benzodiazepines, including midazolam, in this 
patient population is currently not recommended 
[35]. In the early 1980s, benzyl alcohol has been 
also associated to a neonatal toxic syndrome 
attributed to the practice of flushing out umbilical 
catheters with solutions containing this substance 
and characterized by CNS depression, respiratory 
distress and severe metabolic acidosis [36]: as a 
consequence, the FDA recommended that fluids 
containing benzyl alcohol had not to be used in 
preterm newborns. 
The safety assessment of parabens present 
in pediatric oral formulations needs to take into 
account their beneficial antimicrobial effects, so 
their withdrawal may increase the risk of infection 
in neonates. However, while acceptable daily 
intake has been established for adults [37], this 
has not been assigned to neonates. Recently, the 
presence of parabens in blood circulation of 196 
neonates from the UK and Estonia confirm a 
systemic exposure to these compounds following 
administration of routine medicines [38]: this 
is of concern, being the exposure at high doses 
associated to hyperbilirubinemia and oestrogenic 
effects [6]. 
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Antioxidants such as sulfites should be 
responsible for the development of symptoms 
such as wheezing or dyspnoea and non-
immunologic anaphylactoid reactions have also 
been reported [39]: for these reasons, inhaled 
formulations for asthmatic subjects have been 
revised by eliminating the presence of sulfites. 
Sodium metabisulphite (present in oral, parenteral 
and topical formulations) is found in inotropes 
such as dopamine and dobutamine, commonly 
used to treat haemodynamic insufficiency in the 
first days of life, to maintain the stability of these 
molecules [40].
Another important aspect regards the use of 
natural or artificial sweeteners to modify the 
organoleptic properties of paediatric formulations, 
with the aim to improve palatability and 
compliance (for example multivitamins and 
domperidone oral solutions). Among the natural 
sweeteners, lactose and sorbitol may cause 
gastrointestinal symptoms in intolerant subjects 
[41], while sucrose is potentially cariogenic [42]. 
As regards artificial sweeteners, aspartame as a 
source of phenylalanine may be harmful in subjects 
affected by phenylchetonuria [43] and has been 
associated with headache and seizures [44], while 
saccharin could increase the risk of developing 
cancer or dermatological reactions [45]. The use 
of sweetening agents in formulations for neonates 
is not recommended due to a lack of established 
safety data [2].
Finally, pharmaceutical products contain dif-
ferent “E number” additives, including artificial 
colourants, that could have a negative impact on 
children behaviour or could lead to anaphylactoid 
reactions [2]. 
Literature data
From the analysis of the literature, limited 
to a relatively few number of articles (Tab. 1), 
emerges that almost all drugs used in neonates 
(including those licensed) contain at least one 
potentially harmful excipient and the safety 
of the majority of these excipients is not easily 
assessable based on information contained in the 
SPCs. 
A European observational study described the 
extent of the administration of eight potentially 
harmful excipients (parabens, benzoates, benzal-
konium chloride, saccharin sodium, sorbitol, 
propylene glycol, ethanol, polysorbate 80) in 89 
third-level NICUs from 21 countries. Among 
2,095 prescriptions (530 different products) 
administered to 726 neonates (477 preterm), the 
presence of potentially harmful excipients was 
found in 31% of prescriptions (142 products) and 
involved 456 neonates (63%). Parabens were used 
most frequently, followed by propylene glycol 
and benzoates. Major determinants resulted 
geographical area, gestational age and route of 
administration. In detail, variation of excipient 
administration reflected prescription behaviour 
among countries (for example the different 
proportion of vitamin prescriptions containing 
parabens or the non use of domperidone con-
taining saccharin sodium in the East Europe); 
term neonates were less likely to receive 
parabens, benzoates and ethanol; enteral and 
topical formulations contained more frequently 
potentially harmful excipients. The authors 
concluded that a few commonly used medicines 
were responsible for a large part of potentially 
Table 1. Summary of studies reporting exposure to potentially harmful excipients in NICUs.
Reference Country/area
Study 
period
Number 
of 
neonates
Number of 
prescriptions
Number 
of 
products
Number of 
products 
containing 
PHE  
(%)
Number 
of PHE  
(%)
Number 
of 
exposed 
neonates 
(%)
Nellis, 2015 [46] Europe 1 day 726 2,095 530 142 (27%) n.i. 456 (63%)
Garcia-Palop, 2016 [47] Spain n.i. n.i. n.i. 101 40 (40%) n.i. n.i.
Fister, 2015 [1] Slovenia 1 month 48 n.i. 27 18 (66%) 29 (48%) 48 (100%)
Souza, 2014 [48] Brazil 3 months 79 1,303 77 48 (62%) 57 (66%) 78 (99%)
Lass, 2012 [49] Estonia 1 year 348 1,961 107 73 (68%) 47 (38%) 339 (97%)
Whittaker, 2009 [14] UK 1 year 38 n.i. n.i. n.i. 7 (35%) n.i.
Shehab, 2009 [30] USA 1 year 1,190 170 n.i. 15 2 459 (39%)
Butler, 2007 [50] UK 4 weeks 14 n.i. 29 16 (56%) 4 14 (100%)
In the last two rows of the penultimate column the lack of percentages is justified by the fact that the last two studies were focused only on 
2 and 4 specific potentially harmful excipients. 
PHE: potentially harmful excipient; n.i.: not indicated.
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harmful excipients, therefore a substitution or 
a reformulation of products may spare many 
neonates from unnecessary exposure [46].
Similar data referred to a single unit/country 
have been reported by other authors.
Harmful excipients present in medicines given 
to neonates in Spain have been detected: 40% of 
drugs commonly used (101 different products), 
32% of intravenous formulations and 62% of 
oral formulations contained at least one harmful 
excipient. As regards intravenous formulations, 
in 11% of cases more than one harmful excipient 
was present (sodium metabisulphite, ethanol, 
benzyl alcohol). Fifty percent of oral formulations 
contained two or more excipients, mainly parabens 
and sorbitol; 25% of intravenous formulations 
(diazepam, dopamine, sodium heparin and naloxone) 
and 19% of oral formulations (loperamide, carnitine, 
acyclovir) contained excipient amounts greater than 
the adult maximum when administered at doses 
recommended in neonates [47].
A prospective cross-sectional study was 
performed to determine the prevalence of excipient 
exposure in 48 newborns (9 preterm) admitted to the 
Department of Neonatology, Children’s Hospital in 
Ljubljana (Slovenia) during a one-month period. 
Twenty-seven different pharmaceutical preparations 
were prescribed (78% industrially manufactured 
and 22% made at the hospital pharmacy), 12 
for oral use and 10 by intravenous route. The 
most commonly administered medicines were 
antibiotics, antianaemics and vitamins, only one-
third approved for use in neonates. Sixty excipients 
were present in 23/27 preparations, one-fourth 
classified as potentially harmful and 23% known 
to be harmful contained in 66% of preparations: all 
newborns received at least one potentially harmful 
excipient. Among excipients known to be harmful 
for neonates, ethanol, propylene glycol, saccharin 
sodium and benzoates were present in at least 
two pharmaceutical preparations of antibiotics 
(intravenous formulations), iron, vitamins and 
antifungals (oral formulations) [1].
The exposure to excipients among neonates 
hospitalized in the NICU of a public hospital 
in Brasilia (Brazil) was investigated during a 
three-month period. Seventy-nine newborns 
(64 preterm) received 1,303 prescriptions (77 
different formulations related to 70 different active 
compounds). Of the 77 formulations examined, 48 
(62%) contained excipients classified as potentially 
harmful. In total, 86 excipients were present, 66.2% 
categorized as potentially or known to be harmful. 
Almost all neonates (98.7%) were exposed at least to 
one excipient known to be harmful with differences 
among preterm and term newborns: preterms 
resulted at higher risk of exposure to polysorbate 
80 and propylene glycol, while full-term neonates 
presented greater risks in relation to ethanol and 
methylparaben [48]. 
In a prospective cohort study, all medicines 
prescribed to 348 neonates (176 preterm) admitted 
to two Hospitals in Estonia (Tartu University 
Hospital and Tallinn Children’s Hospital) during a 
1-year period were recorded and analysed for their 
excipient content. A total of 123 excipients were 
found in 83% of 1,961 prescriptions (107 different 
medicines). 47/123 (38%) of these excipients were 
classified as potentially or known to be harmful 
(mostly parabens and sodium metabisulphite). 
Two thirds of parenteral products contained some 
potentially harmful excipients, while all of the 
rectal, topical, inhalatory and oral formulations 
contained at least one potentially harmful excipient. 
Almost all treated neonates (97%) were exposed 
at least to one potentially harmful excipient and 
88% received one of the eight excipients known 
to be harmful for neonates: no differences were 
observed between preterm and term neonates. 57% 
of neonates were exposed to parabens, known to 
cause harm but used as preservatives in parenteral 
formulations of gentamicin. Oral suspensions 
of simeticone, the second commonly prescribed 
medicine given to 31% of neonates, contained two 
excipients known to be harmful (sodium benzoate 
and saccharin sodium) and three potentially harmful 
(sodium cyclamate, sorbic acid, colloidal anhydrous 
silica) [49]. 
Excipient exposure after use of oral liquid 
medications was retrospectively analysed in 38 
preterm infants (BW < 1,500 g, GA ≤ 30 weeks) 
admitted to the NICU of University Hospital in 
Leicester (UK) between June 2005 and July 2006 
with a diagnosis of chronic lung disease. More 
than 20 excipients were present in the examined 
formulations related to caffeine, furosemide, 
spironolactone, domperidone, dexamethasone, 
bendrofluazide, iron, vitamins: they included ethanol 
and propylene glycol associated to neurotoxicity 
(many infants exceeded the WHO acceptable 
daily intake limit for adults), but also benzoic 
acid, hydroxybenzoate, Ponceau 4R, sorbitol and 
saccharin [14].
Some authors [30] documented neonatal 
exposure to benzyl alcohol and propylene glycol 
present in 15 parenteral medications routinely 
Neonates exposed to excipients: concern about safety
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used in the NICU of the Mott Children’s Hospital, 
University of Michigan. During the 1-year study 
period, 170 episodes of exposure to benzyl alcohol 
and propylene glycol regarding 459 neonates 
have been selected. Higher excipient doses were 
received with medications given by continuous 
infusion, compared to intermittent administration: 
in this subpopulation of neonates, cumulative 
excipient doses were respectively 21 and 180 times 
the acceptable daily intakes of these two drugs. 
Midazolam and lorazepam were involved in over 
two-thirds of exposures.
Other authors [50] analyzed the exposure to 
excipients potentially harmful in neonates admitted 
to a NICU (Princess Royal Maternity Unit, 
Glasgow Hospital, UK) over a period of 4 weeks. 
56% of medicines given to 14 neonates (mean GA 
31 weeks, mean BW 1,650 g) contained excipients 
of concern (ethanol, benzyl alcohol, benzoic acid, 
hydroxybenzoate, sodium metabisulphite). Some 
adverse reactions (ADRs) have been observed: 
gasping syndrome (benzyl alcohol), bronchospasm 
(sodium metabisulphite), bilirubin displacement 
(hydroxybenzoate). Three patients died.
The neonatal literature includes both short-term 
and long-term outcomes of exposure to excipients. 
There are well-documented, even if limited, case 
reports where the use of excipients in neonates has 
led to severe ADRs (Tab. 2).
A baby born at 24 weeks gestation and 
weighing 710 g developed a staphylococcal 
septicaemia initially treated with flucloxacillin 
and vancomycin. After the development of a red 
swollen knee and cheek, intravenous clindamycin 
was administered in place of vancomycin. After 
the third and fourth doses, the neonate suffered 
a profound desaturation and chest splinting that 
required resuscitation and suspension of the 
antibiotic. It was hypothesized the “gasping 
syndrome” due to the benzyl alcohol excipient 
present in the injectable formulation of clindamycin 
[9], as stated in the SPCs of the medicine and 
observed in preterm newborns treated i.v. with 
other drugs containing this preservative.
The same “gasping syndrome” was reported 
also in the 1980s by other authors in relation to 
the presence of benzyl alcohol in medications 
reconstituted with water containing this 
preservative and in bacteriostatic saline solutions 
used to flush catheters, a routine procedure at that 
time to maintain patency of cannulated arteries. 
In detail, sixteen premature infants weighing less 
than 1,500 grams developed a similar clinical 
syndrome characterized by the deterioration of 
multiple organs and died, as a probable result of 
the exposition to 0.9% benzyl alcohol contained 
in bacteriostatic water and NaCl used to flush 
periodically central intravascular catheters [7, 
36]. Elevated levels of benzyl alcohol and its 
metabolites have been also detected in a critically 
ill newborn with RDS and intraventricular 
hemorrhage (IVH) (35 weeks’ gestation), who 
received during the first 7 days of life large 
amounts of this toxic compound contained in 
a bacteriostatic saline solution from repeated 
umbilical arterial catheter flushes [51]. Other 
Table 2. Case reports of suspected adverse reactions (ADRs) related to excipients.
Reference Subject Treatment ADRs Excipient Outcome
Gershanik, 1982 [36] 10 preterm infants flush saline solution gasping syndrome benzyl alcohol death
Brown, 1982 [7] 6 preterm infants flush saline solution gasping syndrome benzyl alcohol death
Anderson, 1984 [51] preterm infant  (35 weeks) flush saline solution gasping syndrome benzyl alcohol recovery
Hiller, 1986 [52] 23 preterm infants flush saline solution severe IVH benzyl alcohol death
Jardine, 1989 [53] 15 preterm infants flush saline solution kernicterus benzyl alcohol death
Hall, 2004 [9] neonate  (24 weeks) clindamycin gasping syndrome benzyl alcohol recovery
Glasgow, 1983 [54] preterm infant  (27 weeks) multivitamin prep. hyperosmolality (ARF) propylene glycol recovery
MacDonald, 1987 [55] 127 preterm infants  (< 1,500 g) multivitamin prep. seizures propylene glycol
recovery (n = 96)/ 
death (n = 31)
Bove, 1985 [56] 8 preterm infants  (< 1,200 g) i.v. vit. E suppl.
renal dysfunction, 
hepatomegaly
polysorbate 20 
and 80 death
Martone, 1986 [57] 14 preterm infants  (≤ 1,250 g) i.v. vit. E suppl.
renal dysfunction, 
hepatomegaly
polysorbate 20 
and 80 death
Masi, 2009 [10] newborn amiodarone cardiogenic shock polysorbate 80, benzyl alcohol recovery
ADRs: adverse reactions; IVH: intraventricular hemorrhage; ARF: acute renal failure.
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authors examined cohorts of neonates before and 
after administration of solutions containing benzyl 
alcohol and underlined a possible association 
between the exposure to this excipient and a 
higher incidence of severe IVH and kernicterus in 
very low birth weight infants [52, 53]. 
A female infant (27-week gestation, body 
weight at birth 890 g) received parenteral nutrition 
from the 3rd day of life and aminophylline 
on the 9th day in association to respiratory 
support and phototherapy. On the 12th day, an 
unexplained acute renal failure was diagnosed. 
When parenteral nutrition was stopped for 48 
h, the serum osmolality decreased. The reason 
of hyperosmolality was identified when a large 
amount of propylene glycol was detected in the 
urine: the main source of this substance was a 
multivitamin preparation (MVI-12) administered 
daily to the newborn with the parenteral nutrition 
solution. Since high amounts of propylene glycol 
have been detected in other infants treated with 
the same parenteral multivitamin complex, 
the multivitamin preparation was immediately 
removed from all parenteral nutrition solutions 
used in the nursery [54]. Other authors [55] 
reported an increased incidence of seizures, 
dose-related (33% vs 14%), in very low birth 
weight infants (BW < 1,500 grams) exposed to 
two different concentrations of propylene glycol, 
300 mg and 3 g/day, contained in the same 
multivitamin preparation. 
An unusual clinical syndrome was described 
in 1984, after a new i.v. vitamin E supplement 
(E-Ferol) containing high concentrations of poly-
sorbate 20 and 80 was introduced in the market. 
This syndrome, characterized by thrombo-
cytopenia, renal dysfunction, hepato megaly and 
ascites, resulted fatal in 8 preterm newborns 
(BW < 1,200 g) who had received high doses of 
E-Ferol for a long period [56] and occurred in 
other 14 neonates who received more than 20 U/
kg of E-Ferol [57]. Finally, a newborn presenting 
with supraventricular tachycardia developed 
cardio genic shock and multiple organ dysfunction 
thirty minutes after receiving a high loading 
dose of intravenous amiodarone (30-minute 
infusion). Since the highest serum concentra-
tions of amiodarone never exceeded the usual 
steady-state values, it has been hypothesized that 
the two excipients present in the i.v. com mer-
cial formulation, benzyl alcohol and polysorbate 
80, could have precipitated the cardiogenic 
shock [10].
Conclusions 
Because of their lack of pharmacological action, 
excipients have always been considered inert agents 
and for this reason underestimated. However, in the 
last years more interest grew on excipients because 
of safety concerns, particularly in the neonatal 
population where the immaturity of organ systems 
and metabolic pathways cannot always guarantee 
their efficient removal. The EMA has published 
a draft guideline on pharmaceutical development 
of medicines for paediatric use which contains 
a section on excipients. However, this guideline 
includes a useful approach to risk assessment but 
does not indicate how to handle uncertainty [4]. 
The use of excipients in neonatal formulations 
is driven by functional requirements, but should be 
justified through a risk-based assessment [58]. 
Some factors have to be considered in case of 
exposure to excipients: the safety profile of the 
excipient, how the medication containing the 
excipient is given (dosage and frequency, route of 
administration, duration of therapy), the existence 
of alternatives and the regulatory status. In 
addition, two other aspects need to be underlined. 
First, a “background level” of excipient exposure 
has to be taken into account in the first period of 
life, being different excipients present in products 
commonly prescribed to preterm infants such 
as iron, multivitamins and folic acid. Secondly, 
polypharmacy, relatively common in sick neonates, 
could lead to multiple sources of excipients, with 
risk of additive effects [14].
The maximum daily intake is of particular concern. 
The amount of excipients in drug formulations is 
rarely reported, making the evaluation of exposure 
and assessment of harmfulness of these substances 
in neonates very difficult. Moreover, the daily 
toxic threshold, if known, is referred to adults 
and an extrapolation is not always simple, due to 
the physiological characteristics of the neonatal 
population [2]. 
In order to minimize the risks, every excipient 
should be easily identified and explained as regards 
both its amount and function in the medicinal 
product. Moreover, there are clearly differences 
between excipient exposure among countries 
(differences in the choice of active compounds, in 
market availability and regulatory) that need to be 
accounted in research and regulatory actions. 
At present, the EU and US Pediatric Formulation 
Initiatives are working together to create a database 
of Safety and Toxicity of Excipients for Paediatrics 
Neonates exposed to excipients: concern about safety
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(STEP project) to identify the gaps in the excipient 
knowledge and to provide a computerized source 
of information [59], while a new research (SEEN 
project) will contribute to reveal the current status 
of excipients in medicines administered to neonates 
[60]. Moreover, promising collaborative studies 
such as ESNEE project have been conducted in 
Europe with the aim to minimize the risks through 
actions such as excluding excipients associated 
with harm whenever possible or limiting their 
concentrations [19].
Neonatal exposure to potentially harmful 
excipients could be reduced without reformulation 
of existing medicines or introduction in the market 
of new products.
The use of preservative-free solutions in 
premature infants should be possible, for example, 
by packaging medications in single-dose vials 
without preservatives. In addition, in some situations 
it is possible a substitution of a medicine, since 
significant regional variations in administration of 
potentially harmful excipients exist in Europe and 
excipient-free products of the same active compound 
are available in the European market [46]. Some 
authors [49] underlined that in Estonia is available 
and used a formulation of gentamicin, one of the 
most commonly drugs used in neonates, containing 
well-known harmful excipients (parabens) while 
in Europe a paraben-free gentamicin product is 
also registered. This is in line with a Dutch study 
that reported in 22% of cases the existence of an 
alternative formulation to oral liquid medicines 
commonly used in the Netherlands containing 
potentially harmful excipients [17]. Recently, 
a 3-day survey was performed in 21 European 
countries (115 NICUs) to explore the possibility 
to avoid neonatal exposure to potentially harmful 
excipients through product substitution. 456 out 
of 726 neonates (63%) received 137 different 
medicines containing potentially harmful ex-
cipients (43% among 318 administered products). 
Substitution with potential harmful excipient-free 
products was possible in 50% of prescriptions and 
reduced the number of exposed neonates of 44% 
(from 456 to 257) [61]. 
In conclusion, as underlined also by some 
authors [5], for a safe use of excipients in neonates 
manufacturers should adopt best practices and 
regulatory agencies should provide guidance 
for industry, but overall prescribers need to be 
better informed on the quantitative composition 
of medicines and on potential adverse effects of 
excipients.
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